Pharmacy Search
Vertice Login
Menu
close

Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Opioid Overdose

RiVive™ (naloxone hydrochloride) nasal spray

Approval Date: Jul 2023

Note: New Product

Indicated for the emergency treatment of known or suspected opioid overdose, this drug is the second over-the-counter nonprescription opioid overdose drug approved by the FDA

Opvee® (nalmefene hydrochloride) nasal spray

Approval Date: May 2023

Note: New Product

Indicated for the emergency treatment of known or suspected opioid overdose. This is the first approval of nalmefene hydrochloride nasal spray for health care and community use

Medication Name

Approval Date

Category

Description

RiVive™ (naloxone hydrochloride) nasal spray

Jul 2023

Indicated for the emergency treatment of known or suspected opioid overdose, this drug is the second over-the-counter nonprescription opioid overdose drug approved by the FDA

Note: New Product

Opvee® (nalmefene hydrochloride) nasal spray

May 2023

Indicated for the emergency treatment of known or suspected opioid overdose. This is the first approval of nalmefene hydrochloride nasal spray for health care and community use

Note: New Product
lockenvelopephone-handsetmagnifiermenucross-circle